Dobrovolsky V N, Casciano D A, Heflich R H
Division of Genetic and Reproductive Toxicology, HFT-120, National Center for Toxicological Research, 3900 NCTR Road, Jefferson, AR 72079, USA.
Mutat Res. 1999 Jan 25;423(1-2):125-36. doi: 10.1016/s0027-5107(98)00234-6.
Tk+/- transgenic mice were created using an embryonic stem cell line in which one allele of the endogenous thymidine kinase (Tk) gene was inactivated by targeted homologous recombination. Breeding Tk+/- parents produced viable Tk-/- knockout (KO) mice. Splenic lymphocytes from KO mice were used in reconstruction experiments for determining the conditions necessary for recovering Tk somatic cell mutants from Tk+/- mice. The cloning efficiency of KO lymphocytes was not affected by the toxic thymidine analogues 5-bromo-2'-deoxyuridine (BrdUrd) or trifluorothymidine (TFT), or by BrdUrd in the presence of lymphocytes from Tk+/- animals; however, it was easier to identify clones resistant to BrdUrd than to TFT when Tk+/- cells were present. Tk+/- mice were treated with vehicle or 100 mg/kg of N-ethyl-N-nitrosourea (ENU), and after 4 months, the frequency of Tk mutant lymphocytes was measured by resistance to BrdUrd. The frequency of Tk mutants was 22+/-5.9x10-6 in control animals and 80+/-31x10-6 in treated mice. In comparison, the frequency of Hprt mutant lymphocytes, as measured by resistance to 6-thioguanine, was 2.0+/-1.2x10-6 in control animals and 84+/-28x10-6 in the ENU-treated mice. Analysis of BrdUrd-resistant lymphocyte clones derived from the ENU-treated animals revealed point mutations in the non-targeted Tk allele. These results indicate that the selection of BrdUrd-resistant lymphocytes from Tk+/- mice may be used for assessing in vivo mutation in an endogenous, autosomal gene.
使用一种胚胎干细胞系培育出Tk+/-转基因小鼠,其中内源性胸苷激酶(Tk)基因的一个等位基因通过靶向同源重组被灭活。将Tk+/-亲本进行杂交产生了存活的Tk-/-基因敲除(KO)小鼠。KO小鼠的脾淋巴细胞用于重建实验,以确定从Tk+/-小鼠中恢复Tk体细胞突变体所需的条件。KO淋巴细胞的克隆效率不受毒性胸苷类似物5-溴-2'-脱氧尿苷(BrdUrd)或三氟胸苷(TFT)的影响,也不受Tk+/-动物淋巴细胞存在时BrdUrd的影响;然而,当存在Tk+/-细胞时,鉴定对BrdUrd耐药的克隆比鉴定对TFT耐药的克隆更容易。给Tk+/-小鼠注射溶剂或100 mg/kg的N-乙基-N-亚硝基脲(ENU),4个月后,通过对BrdUrd的耐药性来测量Tk突变淋巴细胞的频率。对照动物中Tk突变体的频率为22±5.9×10-6,处理后的小鼠中为80±31×10-6。相比之下,通过对6-硫鸟嘌呤的耐药性测量的Hprt突变淋巴细胞的频率,对照动物中为2.0±1.2×10-6,ENU处理的小鼠中为84±28×10-6。对来自ENU处理动物的BrdUrd耐药淋巴细胞克隆的分析揭示了非靶向Tk等位基因中的点突变。这些结果表明,从Tk+/-小鼠中选择对BrdUrd耐药的淋巴细胞可用于评估内源性常染色体基因的体内突变。